ArticleCancer immunology research2021
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial.Nature communications · 2024Trial
- Focused ultrasound thermal ablation and CD40 agonism reprograms breast tumor immunity to drive regression and memory.Journal for immunotherapy of cancer · 2026Article
- CFD overexpression inhibits CESC progression and enhances TIL therapy efficacy via NOSTRIN and eNOS signaling pathway.Scientific reports · 2026Article
- Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory.bioRxiv : the preprint server for biology · 2026Article
- Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.Nature communications · 2026Article
- Origins of CD8 tissue resident memory.Frontiers in immunology · 2026Review
- Tissue-Resident Memory T Cells: Pioneering New Avenues in Cancer Immunotherapy.Cancer medicine · 2025Review
- Shaping Antitumor Immunity with Peptide Vaccines: Implications of Immune Modulation at the Vaccine Site.Vaccines · 2025Review
- CD7 regulates the persistence of terminally exhausted CD8Cell reports · 2025Article
- Translational Insights into NK Immunophenotyping: Comparative Surface Marker Analysis and Circulating Immune Cell Profiling in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Tumor-Associated Macrophages in Lung Cancer: Origins, Functional Heterogeneity, and Therapeutic Implications.Journal of inflammation research · 2025Review
- Review
- Differential predictive value of resident memory CD8Journal for immunotherapy of cancer · 2024Article
- Article
- A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates.Cancer research communications · 2024Article
- Immune cell trafficking: a novel perspective on the gut-skin axis.Inflammation and regeneration · 2024Review
- Integrated bioinformatics analysis reveals upregulated extracellular matrix hub genes in pancreatic cancer: Implications for diagnosis, prognosis, immune infiltration, and therapeutic strategies.Cancer reports (Hoboken, N.J.) · 2024Article
- Integrin α2 in the microenvironment and the tumor compartment of digestive (gastrointestinal) cancers: emerging regulators and therapeutic opportunities.Frontiers in oncology · 2024Review
- Collagen VI deposition mediates stromal T cell trapping through inhibition of T cell motility in the prostate tumor microenvironment.Matrix biology : journal of the International Society for Matrix Biology · 2023Article
- Barriers to immune cell infiltration in tumors.Journal for immunotherapy of cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Marit M MelssenCarter Immunology Center, University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-6541-9852
Robin S LindsayCarter Immunology Center, University of Virginia, Charlottesville, Virginia.
Katarzyna StasiakCarter Immunology Center, University of Virginia, Charlottesville, Virginia.
Anthony B RodriguezCarter Immunology Center, University of Virginia, Charlottesville, Virginia.
Amanda M BriegelCarter Immunology Center, University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-4015-8238
Salwador CyranowskiCarter Immunology Center, University of Virginia, Charlottesville, Virginia.
Melanie R RutkowskiCarter Immunology Center, University of Virginia, Charlottesville, Virginia.
Mark R ConawayDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
Cornelis J M MeliefDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
Sjoerd H van der BurgDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-6556-0354
Ukpong EyoDepartment of Neuroscience, University of Virginia, Charlottesville, Virginia.
Craig L SlingluffCarter Immunology Center, University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-6664-4373
Victor H EngelhardCarter Immunology Center, University of Virginia, Charlottesville, Virginia. vhe@virginia.edu.
University of Virginia · USOncode Institute · NL
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MINTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2MSupplement - Manipulating microenvironment and vasculature to enhance T cell infiltration into tumorsR01CA233716 · NCI · UNIVERSITY OF VIRGINIA · PI ENGELHARD, VICTOR H, KELLY, KIMBERLY A. · 2019 to 2023
$2.9MImmunotherapeutic Nanoparticle Delivery to Melanoma With MR-Guided Focused UltrasoundR01CA197111 · NCI · UNIVERSITY OF VIRGINIA · PI BULLOCK, TIMOTHY N, ENGELHARD, VICTOR H · 2015 to 2019
$2.6MMicroglial P2Y12 Receptors in Normal Developmental Physiology and SeizuresK22NS104392 · NINDS · UNIVERSITY OF VIRGINIA · PI EYO, UKPONG BASSEY · 2017 to 2020
$813kNCI NIH HHS P30 CA044579NCI NIH HHS R01 CA197111NCI NIH HHS R01 CA233716NIAID NIH HHS T32 AI007496NINDS NIH HHS K22 NS104392
Abstract
CD8
Indexed as
AdultAgedAged, 80 and overAnimalsAntigens, CDBreast NeoplasmsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunologic MemoryIntegrin alpha1Integrin alpha2Lymphocytes, Tumor-InfiltratingMaleMelanomaAntigens, CDIntegrin alpha1Integrin alpha2NR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.